XM does not provide services to residents of the United States of America.
G
G

GSK

News

Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma

BRIEF-Gsk Says Japan Accepts NDA For Blenrep In Multiple Myeloma Sept 17 (Reuters) - GSK plc GSK.L : GSK PLC - JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA Source text for Eikon: ID:nRSQ4071Ea Further company coverage: GSK.L
G

Iteos falls after mid-stage study results for lung cancer drug

BUZZ-Iteos falls after mid-stage study results for lung cancer drug Updates ** Shares of cancer drug developer Iteos Therapeutics ITOS.O slide 23.6% to $12.76 ** Stock had risen 27 .3% t o $21.26 in premarket trade ** Co says its lung cancer drug belrestotug, in combination with GSK's GSK.L drug dostarlimab, showed higher percentage of reduction or
G

Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone

BUZZ-Iteos rises on superior efficacy of lung cancer drug combo vs GSK’s Jemperli alone ** Shares of cancer drug developer Iteos Therapeutics ITOS.O rise 14.7% at $19.16 premarket ** Co says its lung cancer drug, belrestotug, in combination with GSK's GSK.L drug, dostarlimab, showed reduction or disappearance of tumor in 63.3%-76.7% patients, vs
G

Zenas BioPharma shares rise nearly 8% in market debut

UPDATE 2-Zenas BioPharma shares rise nearly 8% in market debut Adds details on U.S. IPO market in paragraph 4-5, details on the company from paragraph 6 onwards Sept 13 (Reuters) - Shares of Bristol-Myers Squibb-backed Zenas BioPharma ZBIO.O rose nearly 8% in their Nasdaq debut on Friday, a sign of recovery for the U.S. initial public offering market in 2024 after two subpar years.
C
G

GSK's Blenrep Receives Breakthrough Therapy Designation In China

BRIEF-GSK's Blenrep Receives Breakthrough Therapy Designation In China Sept 13 (Reuters) - GSK plc GSK.L : GSK PLC - CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP GSK PLC - BLENREP RECEIVES BREAKTHROUGH THERAPY DESIGNATION IN CHINA Source text for Eikon: ID:nRSM0429Ea Further company coverage: GSK.L
G

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.